The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Subgroup analysis of the EPCORE FL-1 trial: efficacy of epcoritamab plus R-squared in R/R FL
Benoit Tessoulin, MD, PhD, Nantes University Hospital Center, Nantes, France, discusses findings from a subgroup analysis of the Phase III EPCORE FL-1 trial (NCT05409066), highlighting that epcoritamab combined with lenalidomide and rituximab (R-squared) demonstrated a consistent benefit across various subgroups of patients with relapsed/refractory (R/R) follicular lymphoma (FL). Dr Tessoulin notes that the combination shows efficacy regardless of factors such as age, comorbidity burden, tumor size, number of prior lines of therapy, or baseline FLIPI score. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
